Clinical Trials Browser

Glioblastoma

NCT01016769 2019-06-26

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1/2 Completed

48 enrolled 15 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00949325 2019-03-11

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Phase 1/2 Completed

24 enrolled 14 charts

Sarcoma

Chondrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02423954 2018-07-02

NivoPlus

Phase 1/2 Terminated

33 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00022724 2018-06-26

CCI-779 in Treating Patients With Malignant Glioma

Phase 1/2 Completed

49 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT01090466 2018-02-06

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Phase 1/2 Completed

15 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01078142 2017-09-11

BERT

Phase 1/2 Completed

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT00921310 2016-12-13

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Phase 1/2 Terminated

12 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01335074 2016-11-15

Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT01206036 2016-01-27

CEPTAS

Phase 1/2 Completed

19 enrolled

Genitourinary

Prostatic Neoplasms

NCT00483262 2013-11-11

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

63 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT01015664 2012-12-17

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Terminated

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01170052 2011-03-16

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1/2 Withdrawn

20 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Clinical Trials

N²M²

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

NivoPlus

CCI-779 in Treating Patients With Malignant Glioma

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

BERT

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

CEPTAS

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)